Non-stimulant ADHD medications are a class of drugs that treat attention-deficit/hyperactivity disorder without the amphetamine or methylphenidate compounds found in traditional stimulants. The FDA has approved four non-stimulant medications specifically for ADHD: atomoxetine (Strattera), guanfacine (Intuniv), clonidine (Kapvay), and viloxazine (Qelbree). These medications work differently from stimulants, take longer to reach full effect, and tend to produce milder side effects, making them a practical option for people who can’t tolerate or prefer to avoid stimulants.
How Non-Stimulants Differ From Stimulants
The biggest practical difference is timing. Stimulants typically start working within 30 to 60 minutes and wear off the same day. Non-stimulants take three to four weeks of daily use before you feel their full effects. This means you won’t notice an immediate change, and it requires patience during the initial weeks to judge whether the medication is working.
In terms of raw symptom reduction, stimulants are generally more powerful. A large network meta-analysis of 133 clinical trials found that amphetamines had the highest efficacy for reducing ADHD symptoms in both children and adults, followed by methylphenidate. Atomoxetine, the most studied non-stimulant, showed a moderate effect size roughly 40-55% as strong as amphetamines depending on the population studied. That said, the picture gets more nuanced when you look at specific cognitive skills. A meta-analysis comparing long-term use of methylphenidate and atomoxetine found comparable improvements in executive functions like planning, mental flexibility, and sustained attention, with medium to large effect sizes for both drugs across most cognitive domains.
Non-stimulants also carry no risk of abuse or dependence, which is why they aren’t classified as controlled substances. Stimulants are Schedule II drugs with recognized potential for misuse.
The Four FDA-Approved Options
Atomoxetine (Strattera)
Atomoxetine was the first non-stimulant approved for ADHD and remains the most widely prescribed. It works by increasing the availability of norepinephrine in the brain, a chemical messenger involved in attention and impulse control. Unlike stimulants, which flood the brain’s reward pathways with dopamine, atomoxetine’s mechanism is more targeted and gradual. It’s approved for both children (6 and older) and adults. Common side effects include decreased appetite, nausea, and fatigue, particularly in the first few weeks as your body adjusts.
Viloxazine (Qelbree)
Viloxazine is the newest FDA-approved non-stimulant, indicated for adults and children aged 6 and older. It also increases norepinephrine activity, with some additional effects on serotonin signaling. The most commonly reported side effects are drowsiness, nausea, and headache. Because it’s newer, it tends to be prescribed when atomoxetine hasn’t worked well or when a different side effect profile is preferred.
Guanfacine (Intuniv) and Clonidine (Kapvay)
These two medications belong to a different class entirely. Originally developed to treat high blood pressure, they work by activating specific receptors in the prefrontal cortex, the part of the brain responsible for planning, impulse control, and working memory. Guanfacine strengthens the connections between neurons in this region, essentially helping the prefrontal cortex do its job of filtering distractions and regulating behavior. Clonidine works through a similar but less selective mechanism.
Because they lower blood pressure, drowsiness and sedation are common, especially early in treatment. Your blood pressure and heart rate will need to be checked during the first few months and periodically afterward. These medications also require gradual dose increases when starting and gradual decreases when stopping, since abrupt changes can cause blood pressure to rebound. Both are approved for children aged 6 to 17 and are often prescribed alongside stimulants to address symptoms like hyperactivity, impulsivity, or difficulty sleeping that stimulants alone don’t fully control.
Why Someone Might Choose a Non-Stimulant
Non-stimulants are sometimes the first choice, but more often they’re tried after stimulants have caused problems or haven’t been effective enough on their own. Common reasons include:
- Intolerable stimulant side effects. Some people experience significant anxiety, insomnia, appetite loss, or elevated heart rate on stimulants that doesn’t resolve with dose adjustments.
- History of substance use. Because non-stimulants have no abuse potential, they’re often preferred for people with a current or past substance use disorder.
- Co-occurring conditions. Tic disorders, severe anxiety, or high blood pressure can all be worsened by stimulants. Non-stimulants, particularly guanfacine and clonidine, may actually improve tics and anxiety while treating ADHD.
- Preference for around-the-clock coverage. Non-stimulants stay active in your system continuously, without the peaks and valleys that come with stimulant dosing. This can help with early morning functioning and evening symptoms.
- Combination therapy. Non-stimulants are frequently added to a stimulant regimen rather than replacing it. This approach targets different brain systems simultaneously and can address residual symptoms.
Off-Label Non-Stimulant Options
Beyond the four FDA-approved medications, some doctors prescribe bupropion (commonly known by the brand name Wellbutrin) off-label for ADHD. Bupropion increases both norepinephrine and dopamine, which gives it a mechanism somewhat closer to stimulants than other non-stimulant options. In three head-to-head studies, bupropion performed comparably to methylphenidate in reducing ADHD symptoms in children. Evidence in adults is less robust, with reviews describing the data as low quality, though some benefit over placebo has been shown in trials lasting at least six weeks.
Bupropion is particularly appealing for adults who have both ADHD and depression, since it’s also an approved antidepressant. It’s not a controlled substance and doesn’t carry abuse risk. However, because it lacks FDA approval specifically for ADHD, insurance coverage can be inconsistent, and there’s less standardized guidance on optimal dosing for attention symptoms.
What to Expect When Starting
The adjustment period for non-stimulants requires more patience than most people anticipate. During the first one to two weeks, you may notice side effects like drowsiness or nausea before you notice any improvement in focus or impulsivity. The therapeutic benefits build gradually, and three to four weeks is a reasonable minimum before deciding whether the medication is helping. Some people need six to eight weeks at the right dose to see the full picture.
Your doctor will likely start at a low dose and increase it over several weeks. For guanfacine and clonidine, blood pressure and heart rate checks are standard during this titration period and at regular intervals afterward, typically every 6 to 12 months once you’re on a stable dose. Atomoxetine and viloxazine don’t lower blood pressure, so cardiovascular monitoring is less intensive, though routine vital sign checks still apply.
One practical advantage worth noting: because non-stimulants aren’t controlled substances, prescriptions can include refills and don’t require a new written prescription each month. For many people, this alone removes a significant logistical burden that comes with stimulant prescriptions.